Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABI 110

Next Previous
X
Search
Drug Profile

ABI 110

Alternative Names: ABI-110

Latest Information Update: 13 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avirmax Biopharma
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Polypoidal choroidal vasculopathy; Wet age-related macular degeneration
  • Preclinical Diabetic macular oedema

Most Recent Events

  • 13 Aug 2024 Phase-I/II clinical trials in Polypoidal choroidal vasculopathy (In the elderly, In adults) in USA (Intravitreous), (NCT06550011)
  • 13 Aug 2024 Phase-I/II clinical trials in Wet age-related macular degeneration (In adults, In the elderly) in USA (Intravitreous) (NCT06550011)
  • 30 May 2024 The U.S. Food and Drug Administration (FDA) approves IND application for ABI 110 in Wet age-related macular degeneration and Polypoidal choroidal vasculopathy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top